CAMPATH-1H (Cambridge University).
CAMPATH-1H, a T-cell-depleting, humanized monoclonal antibody, is under development by LeukoSite and ILEX for the potential treatment of chronic lymphocytic leukemia (CLL). In August 1998, ILEX completed enrollment of a pivotal clinical trial of CAMPATH-1H in the treatment of CLL. The study has enrolled 94 patients at 20 centers in the US and Europe. It is anticipated that achievement of the target response would result in a biologics license application being filed with the FDA in mid-1999. Preliminary unaudited results reported by one of the clinical sites were positive. Additional potential therapeutic areas include vasculitis and multiple sclerosis. Preliminary studies have also shown the antibody may reverse acute renal transplant rejection episodes and be useful in ex vivo purging of bone marrow to remove potentially malignant cells. The US FDA has granted Fast Track designation to CAMPATH. The product has orphan drug status.